212 related articles for article (PubMed ID: 38335281)
1. Sequential CRISPR screening reveals partial NatB inhibition as a strategy to mitigate alpha-synuclein levels in human neurons.
Santhosh Kumar S; Naseri NN; Pather SR; Hallacli E; Ndayisaba A; Buenaventura C; Acosta K; Roof J; Fazelinia H; Spruce LA; Luk K; Khurana V; Rhoades E; Shalem O
Sci Adv; 2024 Feb; 10(6):eadj4767. PubMed ID: 38335281
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis for N-terminal alpha-synuclein acetylation by human NatB.
Deng S; Pan B; Gottlieb L; Petersson EJ; Marmorstein R
Elife; 2020 Sep; 9():. PubMed ID: 32885784
[TBL] [Abstract][Full Text] [Related]
3. Randomized CRISPR-Cas Transcriptional Perturbation Screening Reveals Protective Genes against Alpha-Synuclein Toxicity.
Chen YC; Farzadfard F; Gharaei N; Chen WCW; Cao J; Lu TK
Mol Cell; 2017 Oct; 68(1):247-257.e5. PubMed ID: 28985507
[TBL] [Abstract][Full Text] [Related]
4. Cellular α-synuclein pathology is associated with bioenergetic dysfunction in Parkinson's iPSC-derived dopamine neurons.
Zambon F; Cherubini M; Fernandes HJR; Lang C; Ryan BJ; Volpato V; Bengoa-Vergniory N; Vingill S; Attar M; Booth HDE; Haenseler W; Vowles J; Bowden R; Webber C; Cowley SA; Wade-Martins R
Hum Mol Genet; 2019 Jun; 28(12):2001-2013. PubMed ID: 30753527
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-based identification of N-terminal acetylation in synucleinopathies.
Bae EJ; Lee SJ
Trends Neurosci; 2024 May; 47(5):324-325. PubMed ID: 38553385
[TBL] [Abstract][Full Text] [Related]
6. Modulation of α-synuclein in vitro aggregation kinetics by its alternative splice isoforms.
Röntgen A; Toprakcioglu Z; Tomkins JE; Vendruscolo M
Proc Natl Acad Sci U S A; 2024 Feb; 121(7):e2313465121. PubMed ID: 38324572
[TBL] [Abstract][Full Text] [Related]
7. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
[TBL] [Abstract][Full Text] [Related]
8. Modeling native and seeded Synuclein aggregation and related cellular dysfunctions in dopaminergic neurons derived by a new set of isogenic iPSC lines with SNCA multiplications.
Iannielli A; Luoni M; Giannelli SG; Ferese R; Ordazzo G; Fossati M; Raimondi A; Opazo F; Corti O; Prehn JHM; Gambardella S; Melki R; Broccoli V
Cell Death Dis; 2022 Oct; 13(10):881. PubMed ID: 36261424
[TBL] [Abstract][Full Text] [Related]
9. Alpha-synuclein induces the unfolded protein response in Parkinson's disease SNCA triplication iPSC-derived neurons.
Heman-Ackah SM; Manzano R; Hoozemans JJM; Scheper W; Flynn R; Haerty W; Cowley SA; Bassett AR; Wood MJA
Hum Mol Genet; 2017 Nov; 26(22):4441-4450. PubMed ID: 28973645
[TBL] [Abstract][Full Text] [Related]
10. The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease.
Yasuda T; Mochizuki H
Apoptosis; 2010 Nov; 15(11):1312-21. PubMed ID: 20221696
[TBL] [Abstract][Full Text] [Related]
11. Loss of α-Synuclein Does Not Affect Mitochondrial Bioenergetics in Rodent Neurons.
Pathak D; Berthet A; Bendor JT; Yu K; Sellnow RC; Orr AL; Nguyen MK; Edwards RH; Manfredsson FP; Nakamura K
eNeuro; 2017; 4(2):. PubMed ID: 28462393
[TBL] [Abstract][Full Text] [Related]
12. Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene.
Chen Y; Dolt KS; Kriek M; Baker T; Downey P; Drummond NJ; Canham MA; Natalwala A; Rosser S; Kunath T
Eur J Neurosci; 2019 Feb; 49(4):510-524. PubMed ID: 30472757
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-Cas9-Edited SNCA Knockout Human Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons and Their Vulnerability to Neurotoxicity.
Inoue S; Nishimura K; Gima S; Nakano M; Takata K
Biol Pharm Bull; 2023; 46(3):517-522. PubMed ID: 36858582
[TBL] [Abstract][Full Text] [Related]
14. Trehalose does not improve neuronal survival on exposure to alpha-synuclein pre-formed fibrils.
Redmann M; Wani WY; Volpicelli-Daley L; Darley-Usmar V; Zhang J
Redox Biol; 2017 Apr; 11():429-437. PubMed ID: 28068606
[TBL] [Abstract][Full Text] [Related]
15. Sequential or Simultaneous Injection of Preformed Fibrils and AAV Overexpression of Alpha-Synuclein Are Equipotent in Producing Relevant Pathology and Behavioral Deficits.
Negrini M; Tomasello G; Davidsson M; Fenyi A; Adant C; Hauser S; Espa E; Gubinelli F; Manfredsson FP; Melki R; Heuer A
J Parkinsons Dis; 2022; 12(4):1133-1153. PubMed ID: 35213388
[TBL] [Abstract][Full Text] [Related]
16. Honokiol decreases alpha-synuclein mRNA levels and reveals novel targets for modulating alpha-synuclein expression.
Fagen SJ; Burgess JD; Lim MJ; Amerna D; Kaya ZB; Faroqi AH; Perisetla P; DeMeo NN; Stojkovska I; Quiriconi DJ; Mazzulli JR; Delenclos M; Boschen SL; McLean PJ
Front Aging Neurosci; 2023; 15():1179086. PubMed ID: 37637959
[TBL] [Abstract][Full Text] [Related]
17. In vivo cross-linking reveals principally oligomeric forms of α-synuclein and β-synuclein in neurons and non-neural cells.
Dettmer U; Newman AJ; Luth ES; Bartels T; Selkoe D
J Biol Chem; 2013 Mar; 288(9):6371-85. PubMed ID: 23319586
[TBL] [Abstract][Full Text] [Related]
18. Unbiased Screens for Modifiers of Alpha-Synuclein Toxicity.
Höllerhage M; Bickle M; Höglinger GU
Curr Neurol Neurosci Rep; 2019 Feb; 19(2):8. PubMed ID: 30739256
[TBL] [Abstract][Full Text] [Related]
19. 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model.
Underwood R; Gannon M; Pathak A; Kapa N; Chandra S; Klop A; Yacoubian TA
Acta Neuropathol Commun; 2021 Jan; 9(1):13. PubMed ID: 33413679
[TBL] [Abstract][Full Text] [Related]
20. DJ-1 Acts as a Scavenger of α-Synuclein Oligomers and Restores Monomeric Glycated α-Synuclein.
Atieh TB; Roth J; Yang X; Hoop CL; Baum J
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
